{
  "nct_id": "NCT33249630",
  "indication": "Epilepsy",
  "phase": "Phase 1",
  "sample_size": 328,
  "duration_weeks": 20,
  "dropout_rate": 0.23,
  "primary_endpoints": [
    "Seizure-free days"
  ],
  "secondary_endpoints": [
    "Seizure frequency",
    "Seizure-free days"
  ],
  "blinding": "double-blind",
  "control_arm": "placebo",
  "outcome_summary": "Study no significant difference compared to placebo.",
  "success": false,
  "failure_reason": "Dosing limitations due to side effects"
}